Clinical Trial Update: A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and antiviral effect of experimental drugs in combination with peginterferon alfa-2a and ribavirin in people with Hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2018-06-19